

molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. *Oncogene* 1999; 18:5278-92.

4. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. *Blood* 2001; 97:3589-95.
5. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. *Nat Genet* 1996; 12:144-8.
6. Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-kit-mediated cytokine-independent survival and proliferation in human leukemia cells. *Blood* 2001; 97:3559-67.
7. Gelmetti V, Zhang J, Farelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. *Mol Cell Biol* 1998; 18:7185-91.
8. Ihle JN. Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. *Adv Cancer Res* 1996; 68: 23-65.
9. Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M, et al. Overexpression of translocation-associated fusion gene of FGFR1, MYC, NPM1, and DEK, but absence of the translocations in acute myeloid leukemia – a microarray analysis. *Haematologica* 2002; 87:569-77.
10. Bruserud O, Huang TS, Glenjen N, Gjertsen BT, Foss B. Liptin in human acute myelogenous leukemia (AML): studies of in vivo levels and in vitro effects on native functional AML blasts. *Haematologica* 2002; 87:584-95.
11. Mandelli F, Petti MC, Lo Coco F. Therapy of acute myeloid leukemia: towards a patient-oriented, risk adapted approach. *Haematologica* 1998; 83:1015-23.

Inside Haematologica: clinical follow-up after autologous stem cell transplantation in patients with multiple myeloma

In this issue, Alegre *et al.*¹ report data showing that the patterns of relapse of multiple myeloma after high-dose therapy are very heterogeneous, indicating the need for an individual approach during clinical follow-up after transplantation. The authors also comment that new drugs such as thalidomide may modify the outcome of these patients following transplantation. For a better comprehension, the reader is referred to pertinent papers on this topic that have recently appeared in *Haematologica*.²⁻¹⁶

References

1. Alegre A, Granda A, Martinez-Chamorro C, Diaz-Mediavilla J, Martinez R, Garcia-Laraña J, et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. *Haematologica* 2002; 87: 609-14.
2. Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. *Haematologica* 2000; 85: 52-8.
3. Patriarca F, Damiani D, Fanin R, Grimaz S, Geromin A, Cerno M, et al. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. *Haematologica* 2000; 85:269-74.
4. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Florida P, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. *Haematologica* 2000; 85:800-5.
5. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R, et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. *Haematologica* 2000; 85:930-4.
6. Corso A, Arcaini L, Mangiacavalli S, Astori C, Orlandi E, Lorenzi A, et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. *Haematologica* 2001; 86:394-8.
7. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. *Haematologica* 2001; 86:399-403.
8. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. *Haematologica* 2001; 86:404-8.
9. Del Canizo M, Amigo M, Hernandez JM, Sanz G, Nunez R, Carreras E, et al. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation. *Haematologica* 2000; 85:403-9.
10. Tosi P, Ronconi S, Zamagni E, Cellini C, Grafone T, Cangini D, et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. *Haematologica* 2001; 86: 409-13.
11. Palumbo A, Triolo S, Baldini L, Callea V, Capaldi A, De Stefano V, et al. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. *Haematologica* 2000; 85:508-13.
12. Steingrimsdottir H, Gruber A, Bjorkholm M, Svensson A, Hansson M. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. *Haematologica* 2000; 85:832-8.
13. Tosi P, Ronconi S, Zamagni E, Cellini C, Grafone T, Cangini D, et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. *Haematologica* 2001; 86:409-13.
14. Martinelli G, Tosi P, Ottaviani E, Soverini S, Tura S. Molecular therapy for multiple myeloma. *Haematologica* 2001; 86:908-17.
15. Laurenti L, Chiusolo P, Garzia MG, Zini G, Sora F, Piccirillo N, et al. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. *Haematologica* 2002; 87:59-66.
16. Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. *Haematologica* 2002; 87:408-14.